Evidence map›Paper›PMID 35623493›Full record

ReviewJournal of controlled release : official journal of the Controlled Release Society2022

Molecular design of a pathogen activated, self-assembling mechanopharmaceutical device.

Andrew R Willmer, Jiayi Nie, Mery Vet George De la Rosa, Winnie Wen, Steven Dunne, Gus R Rosania

Open access · hybridAbstract readReview
In one paragraph

Review in Journal of controlled release : official journal of the Controlled Release Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Andrew R WillmerDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address: awillmer@umich.edu.
Jiayi NieDepartment of Biostatistics, University of Southern California, Los Angeles, CA 90089, USA.
Mery Vet George De la RosaDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA.
Winnie WenDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA.
Steven DunneDepartment of Chemistry, University of Michigan, Ann Arbor, MI 48109, USA.
Gus R RosaniaDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA.
University of Michigan–Ann Arbor · USUniversity of Southern California · US

Funding

L-Carnitine As A Metabolic Biomarker of Drug Toxicity RiskR01GM127787 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ROSANIA, GUS R · 2019 to 2022
$2.0M
NIGMS NIH HHS R01 GM127787
6 · The paper itself

Abstract

Weakly basic small molecule drugs like clofazimine can be used as building blocks for endowing cells with unnatural structural and functional elements. Here, we describe how clofazimine represents a first-in-class mechanopharmaceutical device, serving to construct inert, inactive and stimulus responsive drug depots within the endophagolysosomal compartment of cells of living organisms. Upon oral administration, clofazimine molecules self-assemble into stable, membrane-bound, crystal-like drug inclusions (CLDI) that accumulate within macrophages to form a "smart" biocompatible, pathogen activatable mechanopharmaceutical device. Upon perturbation of the mechanism maintaining pH and ion homeostasis of these CLDIs, the inert encapsulated drug precipitates are destabilized, releasing bioactive drug molecules into the cell and its surrounding. The resulting increase in clofazimine solubility activates this broad-spectrum antimicrobial, antiparasitic, antiviral or cytotoxic agent within the infected macrophage. We present a general, molecular design strategy for using clofazimine and other small molecule building blocks for the cytoplasmic construction of mechanopharmaceutical devices, aimed at rapid deployment during infectious disease outbreaks, for the purpose of pandemic prevention.

Indexed as

ClofazimineMacrophagesAnimalsInclusion BodiesMiceMice, Inbred C57BLSolubilityClofazimineDrug-deliveryDrug targetingModeling and simulationPandemic responsePharmacokinetics

Identifiers

PMID35623493
PMCPMC9901583
OpenAlexW4281808824

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.